caa a22 4500 445339268 CHVBK 20180317142806.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1909-7 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1909-7 Lumpectomy Cavity Shaved Margins Do Not Impact Re-excision Rates in Breast Cancer Patients [Elektronische Daten] [Suzanne Coopey, Julliette Buckley, Barbara Smith, Kevin Hughes, Michele Gadd, Michelle Specht] Background: The benefits of taking shaved cavity margins (SCM) at the time of lumpectomy are unclear. We sought to determine if taking SCM decreases re-excision rates by increasing the total breast tissue volume excised. Methods: We undertook a retrospective review of breast cancer patients who underwent lumpectomy from 2004 to 2006. Patients were divided into three groups. Group 1 had lumpectomy alone, group 2 had lumpectomy plus select (1-3) SCM, and group 3 had lumpectomy plus complete (≥4) SCM. Pathologic findings and surgical outcomes were compared between groups. Results: 773 cancers treated by lumpectomy were included in this study; 197 were in group 1, 130 were in group 2, and 446 were in group 3. The mean total volume of breast tissue excised in group 1 (106.6cm3) was significantly larger than the volume excised in groups 2 (79.3cm3) and 3 (76.3cm3). Rates of re-excision and successful breast-conservation therapy (BCT) were not significantly different between groups. Despite a lower total volume of breast tissue excised in groups 2 and 3, there was no significant increase in locoregional recurrence rates (LRR) at median follow-up of 54months. Conclusions: Taking additional SCM during lumpectomy resulted in a significantly lower overall volume of breast tissue excised, with no increase in LRR. Contrary to prior studies, we found that SCM did not decrease re-excision rates or impact the success of BCT. Therefore, the main advantage of taking SCM appears to be that less breast tissue is excised, which could potentially improve cosmetic outcomes. Society of Surgical Oncology, 2011 Coopey Suzanne Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut Buckley Julliette Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut Smith Barbara Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut Hughes Kevin Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut Gadd Michele Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut Specht Michelle Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut Annals of Surgical Oncology Springer-Verlag 18/11(2011-10-01), 3036-3040 1068-9265 18:11<3036 2011 18 10434 https://doi.org/10.1245/s10434-011-1909-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1909-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Coopey Suzanne Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Buckley Julliette Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Smith Barbara Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Hughes Kevin Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Gadd Michele Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Specht Michelle Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/11(2011-10-01), 3036-3040 1068-9265 18:11<3036 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer